ARCA biopharma (ABIO) has received acceptance from Health Canada for its clinical trial application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro to treat atrial fibrillation (AF).

The company expects the clinical trial sites in Canada to be active in the fourth quarter of 2014.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Currently, the company is enrolling patients in the US for the Phase IIb/III GENETIC-AF clinical trial to evaluate Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a treatment for AF.

ARCA founder and CEO Michael Bristow said: "At ARCA, we believe a personalised medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs.

"Gencaro has the potential to be the first genetically targeted treatment for the prevention of this important cardiovascular disorder."

"If the GENETIC-AF trial successfully confirms the atrial fibrillation data analysis from a prior Phase III clinical trial, Gencaro has the potential to be the first genetically targeted treatment for the prevention of this important cardiovascular disorder and provide a much needed treatment option for patients in an area of high unmet medical need."

See Also:

The Phase IIb/III, multi-centre, randomised, double-blind GENETIC-AF clinical trial is comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is planning to enrol only patients with the genetic variant of the beta-1 cardiac receptor.

GENETIC-AF has an adaptive design, under which the company started the trial as a Phase IIB trial in about 200 patients.

The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyse certain data from the Phase IIb portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase III and seek to enrol an additional 420 patients.